Pharmaceuticals

Innoviva prepares for a key investor conference, spotlighting its shift to specialty drugs and navigating questions on its diversified growth strategy.

Reunion Neuroscience hits the investor conference circuit, seeking capital to advance its groundbreaking psychedelic-inspired therapies for depression and anxiety.

With two strategic hires from TriNetX and Canon Medical, Avandra signals an aggressive push to unlock siloed medical imaging data for research and AI.

With a major €12.5M EU funding package, Step Pharma is fast-tracking dencatistat, a novel therapy targeting a key vulnerability in ovarian and endometrial cancers.

New data shows an AI-driven approach is enrolling IBD patients 3.4x faster, promising to accelerate the delivery of novel therapies to those in need.

Amid regional conflict, InterCure reports NIS 265M revenue, enters German market, and makes strategic US moves, showcasing remarkable resilience and growth.

Israeli cannabis firm InterCure posts 11% revenue growth in 2025, showing resilience after conflict and making its first major push into the booming German market.

With major grants from top foundations, Lario Therapeutics expands its precision neuroscience platform, offering new hope for complex neurological disorders.

With its CEO and CFO set for key conferences, Aptar will address investors following a strong sales quarter but facing questions on profitability.

After a major pipeline pivot, Keros Therapeutics faces investors with a new lead drug, a fortified balance sheet, and a high-stakes strategy to prove.

Johnson & Johnson is investing over $1 billion in a new Pennsylvania cell therapy hub, promising revolutionary treatments and thousands of new jobs.

With OSHA standardizing on new high-accuracy tools, companies face a reckoning. Faulty air monitoring puts workers at risk, but new tech offers a defense.

Flatiron Health launches a first-of-its-kind AI platform, merging data from 400,000 patients to revolutionize prostate cancer research and treatment.

A novel drug candidate targeting treatment-resistant kidney disease has begun its long journey through clinical trials, signaling a major strategic push.

A new patent-pending AI platform from Montreal's E-Biotech promises to streamline GMP compliance by integrating with, not replacing, existing systems.

AVEO Oncology's ficlatuzumab advances in a pivotal Phase 3 trial, offering new hope for patients with a difficult-to-treat form of head and neck cancer.

New data on Spyre Therapeutics' SPY003 suggests a twice-yearly shot for IBD is possible, part of a broader strategy to challenge market giants.

The NYC-based private equity firm's oversubscribed Fund IX far exceeds its predecessor, showing robust investor confidence in its long-term strategy.

Unnatural Products inks a major deal with Novartis, using its AI-driven macrocycle technology to develop novel cardiovascular drugs for intractable diseases.

Bausch + Lomb beats Q4 revenue forecasts, propelled by its blockbuster dry eye drug MIEBO, and issues a confident financial outlook for 2026.